Recent research have centered on the overlap of GLP|GIP|glucagon receptor activator therapies and DA neurotransmission. While GCGR agonists are commonly employed for treating type 2 T2DM, their emerging effects on reward circuits, specifically influenced by dopaminergic networks, are gaining substantial interest. This report details a brief assessm